The PS19 transgenic mouse model of tauopathy that expresses a mutant form of human tau and exhibits hyperphoshorylated and insoluble mutant human tau protein [S2] had reduced grip strength and decreased mass and NMJ innervation of muscle, effects that were attenuated with forced expression of neuron‐specific calpastatin.15 This evidence concerns the gene MAPT and tauopathy.